Corporate Update

2022 Achievements & 2023 Plans

February 2, 2023

Fredrik Brag

Chief Executive Officer and Founder

2023 & Beyond: The Big Take Off

Growing penetration of imaging AI in

patient care

  • RSNA 2022 key take away: Imaging AI is now a reality and will have a major impact on disease diagnostics
  • Breakthrough: 3 companies obtained a reimbursement of $650-$1,000 for imaging AI diagnostic solutions in 2022
  • Major study at RSNA showed 92% of LC patients alive after 15 years when diagnosed in Stage 1. Cancer is curable
  • People eligible for LCS in the US has doubled from 7.5m to 15m
  • European Union's initiative to accelerate implementation of LCS national programs, 22m people potentially eligible for LCS
  • The TAM is > $30bn in the US & EU and could double with Asia
  • iBiopsy® LCS SaMD has the highest performance

Growing penetration of imaging AI with

the pharma

  • Major interest for imaging AI by all life sciences stakeholders
  • Pharma operating a stage shift to treat early-stage disease to increase chance of success
  • Imaging AI will revolutionize drug development:
    • Cancer detection & characterization
    • Molecular status prediction
    • Response predictions / Companion diagnostics
  • Median Imaging lab can provide state of the art solutions
  • Median core iCRO business expected to grow significantly

Median intends to sign a strategic

Median intends to sign strategic

commercial partnership for the 2024

partnerships with big pharma

launch of LCS SaMD in the US

2 www.mediantechnologies.com | Company Webcast | February 2, 2023

2022 Achievements

3 www.mediantechnologies.com | Company Webcast | February 2, 2023

2022 Key Performance

As of December 31, 2022

2022 revenue at €23.8M

  • An increase of 16% compared to 2021 revenue (€20.5M).

Order backlog at €60.8M

Cash and cash equivalents at €21.5M

4 www.mediantechnologies.com | Company Webcast | February 2, 2023

25

20

15

10

5

0

Full Year Revenue (m€)

23.8

20.5

13.5

9

Full Year 2019

Full Year 2020

Full Year 2021

Full Year 2022

Nota: company revenue comes from the iCRO BU solely, as iBiopsy® doesn't generate revenue at this stage (R&D)

Release date: January 19, 2023

2022 Macro Geopolitical and Economic Impacts

Small and mid-caps hit by turmoil on

financial markets

  • Small & mid-caps hit by low liquidity
  • Median liquidity: Q4 2022 day-average:
    €141k vs Q1 2022 day-average: €630k
  • Negative asset flows: technology, healthcare and biotechnology equity
  • The need for liquidity by certain funds have had a major impact on the share price

5 www.mediantechnologies.com | Company Webcast | February 2, 2023

China lockdown

  • The Chinese lockdown has had a major impact on our Chinese clients during the bigger part of 2022
  • The situation is expected to come back to normal quite quickly now that the country has opened up again

Inflation & general economic impact

  • Some of our mid size biotechs clients have had funding issues which have slowed down some expected trials. The larger biotechs are now getting funded
  • Perspectum raised $36m at $300m valuation

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Median Technologies SA published this content on 03 February 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 February 2023 11:07:09 UTC.